+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

BRAF Kinase Inhibitors Market 2024-2028

  • PDF Icon

    Report

  • 162 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5601902
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The BRAF kinase inhibitors market is forecasted to grow by USD 1.40 bn during 2023-2028, accelerating at a CAGR of 7.88% during the forecast period. The report on the BRAF kinase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of BRAF kinase inhibitors, the presence of patient assistance programs, and the increasing prevalence of cancer.

The BRAF kinase inhibitors market is segmented as below:

By Product

  • Dabrafenib
  • Sorafenib
  • Vemurafenib
  • Encorafenib

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the expansion of research areas in BRAF kinase inhibitors as one of the prime reasons driving the BRAF kinase inhibitors market growth during the next few years. Also, growing strategic alliances and growing awareness of cancer will lead to sizable demand in the market.

The report on the BRAF kinase inhibitors market covers the following areas:

  • Braf kinase inhibitors market sizing
  • Braf kinase inhibitors market forecast
  • Braf kinase inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BRAF kinase inhibitors market vendors that include Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Fore Biotherapeutics Inc., Jazz Pharmaceuticals Plc, Nerviano Medical Sciences S.r.l, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Pierre Fabre SA, Kinnate Biopharma, and Black Diamond Therapeutics Inc.. Also, the BRAF kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global BRAF kinase inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global braf kinase inhibitors market 2018 - 2022 ($ billion)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Dabrafenib - Market size and forecast 2023-2028
Exhibit 34: Chart on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Dabrafenib - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Dabrafenib - Year-over-year growth 2023-2028 (%)
6.4 Sorafenib - Market size and forecast 2023-2028
Exhibit 38: Chart on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Sorafenib - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Sorafenib - Year-over-year growth 2023-2028 (%)
6.5 Vemurafenib - Market size and forecast 2023-2028
Exhibit 42: Chart on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Vemurafenib - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Vemurafenib - Year-over-year growth 2023-2028 (%)
6.6 Encorafenib - Market size and forecast 2023-2028
Exhibit 46: Chart on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on Encorafenib - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Encorafenib - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Product
Exhibit 50: Market opportunity by Product ($ billion)
Exhibit 51: Data Table on Market opportunity by Product ($ billion)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 68: Market opportunity by Distribution Channel ($ billion)
Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 France - Market size and forecast 2023-2028
Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Asana BioSciences LLC
Exhibit 119: Asana BioSciences LLC - Overview
Exhibit 120: Asana BioSciences LLC - Product / Service
Exhibit 121: Asana BioSciences LLC - Key offerings
12.4 Bayer AG
Exhibit 122: Bayer AG - Overview
Exhibit 123: Bayer AG - Business segments
Exhibit 124: Bayer AG - Key news
Exhibit 125: Bayer AG - Key offerings
Exhibit 126: Bayer AG - Segment focus
12.5 BeiGene Ltd.
Exhibit 127: BeiGene Ltd. - Overview
Exhibit 128: BeiGene Ltd. - Business segments
Exhibit 129: BeiGene Ltd. - Key offerings
Exhibit 130: BeiGene Ltd. - Segment focus
12.6 Black Diamond Therapeutics Inc.
Exhibit 131: Black Diamond Therapeutics Inc. - Overview
Exhibit 132: Black Diamond Therapeutics Inc. - Product / Service
Exhibit 133: Black Diamond Therapeutics Inc. - Key offerings
12.7 F. Hoffmann La Roche Ltd.
Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Fore Biotherapeutics Inc.
Exhibit 139: Fore Biotherapeutics Inc. - Overview
Exhibit 140: Fore Biotherapeutics Inc. - Product / Service
Exhibit 141: Fore Biotherapeutics Inc. - Key offerings
12.9 Jazz Pharmaceuticals Plc
Exhibit 142: Jazz Pharmaceuticals Plc - Overview
Exhibit 143: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 144: Jazz Pharmaceuticals Plc - Key news
Exhibit 145: Jazz Pharmaceuticals Plc - Key offerings
12.10 Kinnate Biopharma
Exhibit 146: Kinnate Biopharma - Overview
Exhibit 147: Kinnate Biopharma - Product / Service
Exhibit 148: Kinnate Biopharma - Key offerings
12.11 Nerviano Medical Sciences S.r.l
Exhibit 149: Nerviano Medical Sciences S.r.l - Overview
Exhibit 150: Nerviano Medical Sciences S.r.l - Product / Service
Exhibit 151: Nerviano Medical Sciences S.r.l - Key offerings
12.12 Novartis AG
Exhibit 152: Novartis AG - Overview
Exhibit 153: Novartis AG - Business segments
Exhibit 154: Novartis AG - Key offerings
Exhibit 155: Novartis AG - Segment focus
12.13 Ono Pharmaceutical Co. Ltd.
Exhibit 156: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 157: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibit 158: Ono Pharmaceutical Co. Ltd. - Key offerings
12.14 Pfizer Inc.
Exhibit 159: Pfizer Inc. - Overview
Exhibit 160: Pfizer Inc. - Product / Service
Exhibit 161: Pfizer Inc. - Key news
Exhibit 162: Pfizer Inc. - Key offerings
12.15 Pierre Fabre SA
Exhibit 163: Pierre Fabre SA - Overview
Exhibit 164: Pierre Fabre SA - Business segments
Exhibit 165: Pierre Fabre SA - Key offerings
Exhibit 166: Pierre Fabre SA - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 167: Inclusions checklist
Exhibit 168: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 169: Currency conversion rates for US$
13.4 Research methodology
Exhibit 170: Research methodology
Exhibit 171: Validation techniques employed for market sizing
Exhibit 172: Information sources
13.5 List of abbreviations
Exhibit 173: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global braf kinase inhibitors market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Product - Market share 2023-2028 (%)
Exhibits 31: Data Table on Product - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Dabrafenib - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Dabrafenib - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Sorafenib - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Sorafenib - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Vemurafenib - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Vemurafenib - Year-over-year growth 2023-2028 (%)
Exhibits 46: Chart on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 47: Data Table on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibits 48: Chart on Encorafenib - Year-over-year growth 2023-2028 (%)
Exhibits 49: Data Table on Encorafenib - Year-over-year growth 2023-2028 (%)
Exhibits 50: Market opportunity by Product ($ billion)
Exhibits 51: Data Table on Market opportunity by Product ($ billion)
Exhibits 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 54: Chart on Comparison by Distribution Channel
Exhibits 55: Data Table on Comparison by Distribution Channel
Exhibits 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 68: Market opportunity by Distribution Channel ($ billion)
Exhibits 69: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 73: Chart on Geographic comparison
Exhibits 74: Data Table on Geographic comparison
Exhibits 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 111: Market opportunity By Geographical Landscape ($ billion)
Exhibits 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 113: Impact of drivers and challenges in 2023 and 2028
Exhibits 114: Overview on Criticality of inputs and Factors of differentiation
Exhibits 115: Overview on factors of disruption
Exhibits 116: Impact of key risks on business
Exhibits 117: Vendors covered
Exhibits 118: Matrix on vendor position and classification
Exhibits 119: Asana BioSciences LLC - Overview
Exhibits 120: Asana BioSciences LLC - Product / Service
Exhibits 121: Asana BioSciences LLC - Key offerings
Exhibits 122: Bayer AG - Overview
Exhibits 123: Bayer AG - Business segments
Exhibits 124: Bayer AG - Key news
Exhibits 125: Bayer AG - Key offerings
Exhibits 126: Bayer AG - Segment focus
Exhibits 127: BeiGene Ltd. - Overview
Exhibits 128: BeiGene Ltd. - Business segments
Exhibits 129: BeiGene Ltd. - Key offerings
Exhibits 130: BeiGene Ltd. - Segment focus
Exhibits 131: Black Diamond Therapeutics Inc. - Overview
Exhibits 132: Black Diamond Therapeutics Inc. - Product / Service
Exhibits 133: Black Diamond Therapeutics Inc. - Key offerings
Exhibits 134: F. Hoffmann La Roche Ltd. - Overview
Exhibits 135: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 136: F. Hoffmann La Roche Ltd. - Key news
Exhibits 137: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 138: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 139: Fore Biotherapeutics Inc. - Overview
Exhibits 140: Fore Biotherapeutics Inc. - Product / Service
Exhibits 141: Fore Biotherapeutics Inc. - Key offerings
Exhibits 142: Jazz Pharmaceuticals Plc - Overview
Exhibits 143: Jazz Pharmaceuticals Plc - Product / Service
Exhibits 144: Jazz Pharmaceuticals Plc - Key news
Exhibits 145: Jazz Pharmaceuticals Plc - Key offerings
Exhibits 146: Kinnate Biopharma - Overview
Exhibits 147: Kinnate Biopharma - Product / Service
Exhibits 148: Kinnate Biopharma - Key offerings
Exhibits 149: Nerviano Medical Sciences S.r.l - Overview
Exhibits 150: Nerviano Medical Sciences S.r.l - Product / Service
Exhibits 151: Nerviano Medical Sciences S.r.l - Key offerings
Exhibits 152: Novartis AG - Overview
Exhibits 153: Novartis AG - Business segments
Exhibits 154: Novartis AG - Key offerings
Exhibits 155: Novartis AG - Segment focus
Exhibits 156: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits 157: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibits 158: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits 159: Pfizer Inc. - Overview
Exhibits 160: Pfizer Inc. - Product / Service
Exhibits 161: Pfizer Inc. - Key news
Exhibits 162: Pfizer Inc. - Key offerings
Exhibits 163: Pierre Fabre SA - Overview
Exhibits 164: Pierre Fabre SA - Business segments
Exhibits 165: Pierre Fabre SA - Key offerings
Exhibits 166: Pierre Fabre SA - Segment focus
Exhibits 167: Inclusions checklist
Exhibits 168: Exclusions checklist
Exhibits 169: Currency conversion rates for US$
Exhibits 170: Research methodology
Exhibits 171: Validation techniques employed for market sizing
Exhibits 172: Information sources
Exhibits 173: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global BRAF kinase inhibitors market: Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Fore Biotherapeutics Inc., Jazz Pharmaceuticals Plc, Nerviano Medical Sciences S.r.l, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Pierre Fabre SA, Kinnate Biopharma, and Black Diamond Therapeutics Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is an expansion of research areas in BRAF kinase inhibitors.'

According to the report, one of the major drivers for this market is the high target affinity and specificity of BRAF kinase inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Asana BioSciences LLC
  • Bayer AG
  • BeiGene Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fore Biotherapeutics Inc.
  • Jazz Pharmaceuticals Plc
  • Nerviano Medical Sciences S.r.l
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA
  • Kinnate Biopharma
  • Black Diamond Therapeutics Inc.